Proteomic Alterations of HDL in Youth with Type 1 Diabetes and their Associations with Glycemic Control: A Case-Control Study by Gourgari, Evgenia et al.
University of Kentucky
UKnowledge
Saha Cardiovascular Research Center Faculty
Publications Cardiovascular Research
3-28-2019
Proteomic Alterations of HDL in Youth with Type
1 Diabetes and their Associations with Glycemic
Control: A Case-Control Study
Evgenia Gourgari
Georgetown University
Junfeng Ma
Georgetown University
Martin P. Playford
National Heart, Lung and Blood Institute
Nehal N. Mehta
National Heart, Lung and Blood Institute
Radoslav Goldman
Georgetown University
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/cvrc_facpub
Part of the Cardiology Commons, and the Circulatory and Respiratory Physiology Commons
This Article is brought to you for free and open access by the Cardiovascular Research at UKnowledge. It has been accepted for inclusion in Saha
Cardiovascular Research Center Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Gourgari, Evgenia; Ma, Junfeng; Playford, Martin P.; Mehta, Nehal N.; Goldman, Radoslav; Remaley, Alan T.; and Gordon, Scott M.,
"Proteomic Alterations of HDL in Youth with Type 1 Diabetes and their Associations with Glycemic Control: A Case-Control Study"
(2019). Saha Cardiovascular Research Center Faculty Publications. 40.
https://uknowledge.uky.edu/cvrc_facpub/40
Authors
Evgenia Gourgari, Junfeng Ma, Martin P. Playford, Nehal N. Mehta, Radoslav Goldman, Alan T. Remaley, and
Scott M. Gordon
Proteomic Alterations of HDL in Youth with Type 1 Diabetes and their Associations with Glycemic Control: A
Case-Control Study
Notes/Citation Information
Published in Cardiovascular Diabetology, v. 18, article no. 43, p. 1-11.
© The Author(s) 2019.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.
Digital Object Identifier (DOI)
https://doi.org/10.1186/s12933-019-0846-9
This article is available at UKnowledge: https://uknowledge.uky.edu/cvrc_facpub/40
Gourgari et al. Cardiovasc Diabetol           (2019) 18:43  
https://doi.org/10.1186/s12933-019-0846-9
ORIGINAL INVESTIGATION
Proteomic alterations of HDL in youth 
with type 1 diabetes and their associations 
with glycemic control: a case–control study
Evgenia Gourgari1* , Junfeng Ma2,3, Martin P. Playford4, Nehal N. Mehta4, Radoslav Goldman3, Alan T. Remaley5 
and Scott M. Gordon6,7
Abstract 
Background: Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density 
lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in 
cholesterol content. Alteration of the HDL proteome can result in dysfunctional HDL particles with reduced ability to 
protect against cardiovascular disease (CVD). The objective of this study was to compare the HDL proteomes of youth 
with T1DM and healthy controls (HC) and to evaluate the influence of glycemic control on HDL protein composition.
Methods: This was a cross-sectional case–control study. Blood samples were obtained from patients with T1DM and 
HC. HDL was isolated from plasma by size-exclusion chromatography and further purified using a lipid binding resin. 
The HDL proteome was analyzed by mass spectrometry using label-free SWATH peptide quantification.
Results: Samples from 26 patients with T1DM and 13 HC were analyzed and 78 HDL-bound proteins were measured. 
Youth with T1DM had significantly increased amounts of complement factor H related protein 2 (FHR2; adjusted 
P < 0.05), compared to HC. When patients were analyzed based on glucose control, several trends emerged. Some 
proteins were altered in T1DM and not influenced by glycemic control (e.g. FHR2) while others were partially or 
completely corrected with optimal glucose control (e.g. alpha-1-beta glycoprotein, A1BG). In a subgroup of poorly 
controlled T1DM patients, inter alpha trypsin inhibitor 4 (ITIH4) was dramatically elevated (P < 0.0001) and this was 
partially reversed in patients with optimal glucose control. Some proteins including complement component C3 
(CO3) and albumin (ALB) were significantly different only in T1DM patients with optimal glucose control, suggesting a 
possible effect of exogenous insulin.
Conclusions: Youth with T1DM have proteomic alterations of their HDL compared to HC, despite similar concentra-
tion of HDL cholesterol. The influence of these compositional changes on HDL function are not yet known. Future 
efforts should focus on investigating the role of these HDL associated proteins in regard to HDL function and their 
role in CVD risk in patients with T1DM.
Trial registration NCT02275091
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Introduction
Patients with type 1 diabetes (T1DM) are at increased 
risk for cardiovascular disease [1]. This risk starts early 
in life as there is evidence of subclinical cardiovascular 
disease (CVD) in youth with T1DM [2]. The primary risk 
factors that have been attributed to CVD in this popu-
lation include poor glycemic control, hypertension, obe-
sity, and dyslipidemia [1, 3]. Dyslipidemia, characterized 
by non-HDL cholesterol > 130 mg/dL was found in 27.7% 
and low HDL < 35 mg/dL in only 3.4% of a large cohort 
of 682 children with T1DM [4]. In the SEARCH study, 
among 512 youth with T1DM and 188 healthy controls, 
the prevalence of low HDL < 35  mg/dL was 10.3%, 7.6% 
and 5% among healthy children and youth with T1DM 
and optimal or suboptimal control, respectively [5]. In 
general, low HDL levels in patients with T1DM is not as 
frequent as other types of dyslipidemia and the HDL pro-
file can often even be favorable in patients with T1DM. 
However, despite the normal HDL cholesterol, the func-
tion of HDL can be impaired in some patients with 
T1DM [6–8]. The primary cardioprotective functions of 
HDL include the following: (i) prevention of the oxida-
tion of LDL (ii) cholesterol efflux from the vessel wall and 
transport of cholesterol to the liver and (iii) anti-inflam-
matory function [9].
Alterations in the protein composition of HDL can 
affect its protective functions [7, 10]. For example, adults 
with T1DM and low levels of the protein apolipopro-
tein A-I (apoA-I) on the HDL particles were more likely 
to develop CVD [7]. Adult patients with T1DM and 
subclinical atherosclerosis have decreased levels of the 
potent antioxidant protein paraoxonase-3 (PON3) and 
PON3 concentration correlates with the anti-inflamma-
tory function of HDL [9]. HDL proteome studies done in 
patients with type 2 diabetes (T2DM) have found altera-
tions of HDL proteins linked to increased CVD risk [11, 
12].
The influence of T1DM on the HDL proteome in youth 
with T1DM has not been reported. Our goal was to test 
the hypothesis that youth with T1DM have protein alter-
ations on HDL that could play a role in modifying HDL 
function and contribute to an increased risk for CVD. 
In this study, SWATH mass spectrometry was used for 
label-free relative quantification of the HDL proteome. 
The protein composition of HDL was compared between 
youth with T1DM and healthy controls (HC) and the 
effect of glycemic control on HDL bound proteins was 
evaluated.
Methods
Study participants
All participants were enrolled in the clinical protocol 
“Identifying children with type 1 diabetes at high risk 
for CVD” (Clinical Trials Number: NCT02275091) that 
was approved by the Georgetown-Howard Universi-
ties Center for Clinical and Translational Science Insti-
tutional Review Board (IRB). Written informed consent 
was obtained from all parents of pediatric patients and 
all adult patients and assent was obtained from all chil-
dren < 18 years old. Youth with T1DM and healthy con-
trols between the ages of 12 and 21  years were eligible 
for participation. Subjects on lipid lowering medications 
were excluded from participation.
Recruitment of study participants was done by send-
ing IRB approved letters to the patients with T1DM 
who are followed at the Pediatric Endocrine Divisions 
of Georgetown University (GU) and Children’s National 
Health System in Washington, DC. Healthy controls were 
recruited mainly by sending letters to families of children 
who had their well-child visits in the pediatric clinic of 
GU.
A research nurse conducted the anthropometric meas-
urements and the BMI z-score was calculated using the 
CDC charts. Lipoprotein concentrations were measured 
using Liposcience NMR spectroscopy at the National 
Institutes of Health Clinical Center as previously 
described [13].
Proteomics experiments
Preparation of samples for proteomics experiments was 
done following a number of steps as previously described 
[14, 15] and briefly summarized below: (1) purification 
of HDL from serum by size-exclusion chromatography; 
(2) pooling of all HDL containing fractions; (3) applica-
tion of pooled HDL to lipid binding resin; (4) washing 
of HDL on resin to remove contaminating proteins; (5) 
trypsin digest of HDL on resin (overnight); (6) wash-
ing of the resin to collect tryptic peptides; (7) reduction 
and carbamidomethylation (DTT and iodoacetamide, 
respectively); and (8) sample desalting using ZipTips. 
The samples were dried down for proteomics analysis by 
using a nanoAcquity UPLC coupled with a TripleTOF 
6600 mass spectrometer. First, we established a protein 
library of all HDL proteins detectable by mass-spectrom-
etry (MS) for the analysis of a sample pool from all the 
subjects (with equal amount of proteins combined). The 
pooled sample was analyzed with 4 consecutive runs 
data in data dependent acquisition (DDA) mode. We 
then ran each sample individually via label-free SWATH 
data independent acquisition (DIA) to quantify each of 
these proteins in the samples. Specifically, peptides in 
each sample were dissolved into 20  µL of 0.1% formic 
acid. For spectra library generation, the pooled sample 
was loaded onto a C18 Trap column (Waters Acquity 
UPLC Symmetry C18 NanoAcquity 10 K 2G V/M, 100 A, 
5 μm, 180 μm × 20 mm) at 15 µL/min for 4 min. Peptides 
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were then separated with an analytical column (Waters 
Acquity UPLC M-Class, peptide BEH C18 column, 300 
A, 1.7  μm, 75  μm × 150  mm) which was temperature 
controlled at 40  °C. The flow rate was set as 400  nL/
min. A 60-min gradient of buffer A (2% ACN, 0.1% for-
mic acid) and buffer B (0.1% formic acid in ACN) was 
used for separation: 1% buffer B at 0 min, 5% buffer B at 
1 min, 45% buffer B at 35 min, 99% buffer B at 37 min, 
99% buffer B at 40  min. The gradient went back to 1% 
buffer B to equilibrate the column for 20  min. The Tri-
pleTOF 6600 mass spectrometer was operated with an 
ion spray voltage of 2.3 kV, GS1 5 psi, GS2 0, CUR 30 psi 
and an interface heater temperature of 150 °C. The mass 
spectra were recorded with Analyst TF 1.7 software in 
the data dependent acquisitions (DDA) mode. Each cycle 
consisted of a full scan (m/z 400–1800) and fifty (IDAs) 
(m/z 100–1800) in the high sensitivity mode with a 2+ 
to 5+ charge state. Rolling collision energy was used. For 
SWATH acquisition, each of the samples was injected 
individually into the same NanoUPLC-MS/MS sys-
tem (same settings as above) but acquired by repeatedly 
cycling through 32 consecutive 25-Da precursor isolation 
windows, generating time-resolved fragment ion spectra 
for all the analytes detectable within the 400–1200  m/z 
precursor range.
Proteomics data analysis
For spectra library generation, raw mass spectra files 
after DDA acquisition of the pooled sample were submit-
ted for combined searches using Protein Pilot version 5.0 
software (Sciex) utilizing the Paragon and Progroup algo-
rithms [16] and the integrated false discovery rate (FDR) 
analysis function [17]. MS/MS data were searched against 
the NCBI Homo Sapiens of the Uniprot-Sprot database 
containing 20,316 entries (downloaded on June 2, 2015). 
Trypsin was selected as the enzyme and carbamidometh-
ylation was set as a fixed modification on cysteine. Vari-
able peptide modifications included only methionine (M) 
oxidation. Other search parameters included instrument 
(TripleTOF 6600), ID Focus (Biological modifications), 
search effort (Thorough), false discovery rate (FDR) 
analysis (Yes), and user modified parameter files (No). 
The proteins were inferred based on the ProGroupTM 
algorithm associated with the ProteinPilot software. The 
detected protein threshold in the software was set to the 
value which corresponded to 1% FDR. Peptides were 
defined as redundant if they had identical cleavage site(s), 
amino acid sequence, and modification.
For the label-free SWATH quantification, data from 
each sample was pre-processed by PeakView 2.1 (Sciex), 
with the default settings: (1) peptide filter: # of peptides 
per protein: 6; # of transitions per peptide: 6; peptide con-
fidence threshold: 99%; FDR threshold: 1%; (2) extracted 
ion chromatogram (XIC) Options: XIC extraction win-
dow (min): 5; XIC width (ppm): 75. Retention time was 
calibrated by selecting 6 peptides with retention time 
across the whole HPLC gradient. Peak of each transition 
produced was then manually checked and curated, with 
only transitions detected in all samples and showing sig-
nal to noise (S/N) > 10 chosen for peak area calculation. 
The peptide response was calculated as the sum of all ion 
intensity for all curated transitions. The sum of response 
of all curated peptides in each protein was used for pro-
tein level quantification (Additional file 1: Table S1). The 
intensity of proteins was then normalized to the total ion 
intensity of each sample, with the ratio of protein repre-
senting the protein level in each sample (Additional file 2: 
Table S2).
Cholesterol efflux analysis
To determine whether any of the proteins of interest are 
related to changes in the cholesterol efflux function of 
HDL, we measured HDL efflux capacity as previously 
described by our group [8]. In summary, HDL cholesterol 
efflux capacity assays were performed using the murine 
macrophage cell line, J774, based on published methods, 
[18–20]. Briefly, 3 × 105 J774  cells/well were plated and 
radiolabeled with 2  µCi of 3H-cholesterol/mL for 24  h. 
ATP-binding cassette transporter A1 (ABCA1) was up-
regulated by means of a 16-h incubation with 0.3 mmol/L 
8-(4-chlorophenylthio)-cAMP. ApoB-depleted plasma 
(2.8%) was added to the efflux medium for 4  h. Liquid 
scintillation counting was added to quantify the efflux of 
radioactive cholesterol from the cells. Efflux was calcu-
lated using the following formula: (µCi of 3H-cholesterol 
in media containing 2.8% apoB-depleted subject plasma-
µCi of 3H-cholesterol in plasma-free media/µCi of 
3H-cholesterol in media containing 2.8% apoB-depleted 
pooled control plasma-µCi of 3H-cholesterol in pooled 
control plasma-free media). The pooled plasma was 
obtained from five healthy adult volunteers. All assays 
were performed in duplicates.
Statistical analysis
Ion intensity data for each protein was tested for normal-
ity using the Shapiro–Wilk test (SigmaPlot 13.0). All pro-
tein ion intensity measurements were  log10 transformed 
prior to analysis. To identify proteins with differential 
abundance between healthy control and T1DM groups 
we used two approaches: (A) Student’s t test was used on 
individual proteins, without correction for multiple com-
parisons. In proteomics data sets, common methods of 
adjustment for multiple comparisons testing often result 
in a high occurrence of false negatives [21]. To reduce 
the risk of omitting true positive hits from this analysis, 
these results were initially screened using more relaxed 
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statistical criteria with a P value threshold of 0.05 with-
out corrections for multiple comparisons. (B) To evaluate 
the data with consideration for multiple testing correc-
tion, we used the two stage step up false discovery rate 
method of Benjamini, Krieger and Yekutieli with a Q 
value cutoff of 5%. The ion intensity dataset included one 
missing data point (out of 3042 observations). The miss-
ing data point was ignored in subsequent calculations. 
Fold-change was calculated as the ion intensity in T1DM 
divided by the same protein’s intensity in the healthy con-
trol group. Linear regression and ANOVA analyses were 
performed under described parameters using GraphPad 
Prism 7 software.
Results
Study population
We analyzed the HDL proteome in 26 patients with 
T1DM and 13 HC (Table 1). Patients were matched for 
age, sex, BMI, and clinical lipid measures. The average 
duration of diabetes was 2.9 ± 1.1  years in the T1DM 
group and the average HbA1c was 8.9 ± 1.8% in the 
T1DM and 5.3 ± 0.3% in the HC, P ≤ 0.001.
HDL proteome analysis
We developed a library for MS-based label-free quanti-
tation of HDL-bound proteins, using a subset of samples 
from each study group. This approach quantified 78 pro-
teins that are present in HDL fractions in both T1DM 
and HC (matched with 229 peptides and 1142 transi-
tions; > 95% confidence) after manual curation (i.e., only 
transitions showing S/N > 10 were selected for quantifica-
tion) (Additional file 1: Table S1).
Analysis of the HDL proteome in all participants 
using an unadjusted t-test revealed 8 proteins that were 
potentially altered among the patients with T1DM and 
HC. Six of these proteins were elevated in HDL of youth 
with T1DM and two of them were decreased (Fig.  1). 
Youth with T1DM had significantly higher protein lev-
els of alpha-1B-glycoprotein (A1BG; P = 0.003), apolipo-
protein A-IV (APOA4; P = 0.037), complement factor H 
(CFAH; P = 0.0488), factor H related protein 2 (FHR2; 
P = 0.0005), inter-alpha trypsin inhibitor 4 (ITIH4; 
P = 0.013), peptidoglycan recognition protein 2 (PGRP2; 
P = 0.017) and lower levels of albumin (ALBU; P = 0.027) 
and complement C3 (CO3; P = 0.015) compared to HC. 
When these results were analyzed with more strict statis-
tical approach by applying a false discovery rate thresh-
old of 5%, only one protein was identified as statistically 
significant, FHR2 (P = 0.039).
To determine if HDL-bound proteins correlate with 
glycemic control, linear regression analysis was used to 
evaluate the relationships between measured proteins 
and HbA1c. Of those proteins potentially altered by type I 
diabetes status, A1BG  (r2 = 0.23, adjusted P = 0.0152) was 
significantly associated with HbA1c (Table 2). To exam-
ine the effect of glycemic control in patients, we divided 
the T1DM cohort into poorly controlled (HbA1c > 7.6%, 
n = 15) and well-controlled (HbA1c ≤ 7.6%, n = 11) 
Table 1 Clinical characteristics of heavy control and T1DM 
patients
P values are derived from t tests with Holm–Sidak correction for multiple 
comparisons
Healthy controls Type 1 diabetes P value
n 13 26 –
Age (years) 16.8 ± 1.4 16.9 ± 1.9 0.99
Female sex, n (%) 11 (84%) 18 (69%) –
BMI z score 0.1 ± 1.0 0.4 ± 0.1 0.79
HbA1c % 5.3 ± 0.3 8.9 ± 1.8 < 0.0001
Diabetes duration – 2.9 ± 1.1 –
hsCRP 0.33 ± 0.2 1.9 ± 3.5 0.60
HDL cholesterol (mg/
dL)
59.0 ± 12.0 59.7 ± 8.6 0.99
LDL cholesterol (mg/
dL)
60.5 ± 28.8 72.6 ± 21.9 0.60
Triglyceride (mg/dL) 81.6 ± 34.5 81.7 ± 36.3 0.99
Fig. 1 The HDL proteome is altered in youth with type 1 diabetes. 
HDL was isolated from youth with T1DM and healthy controls 
then proteome composition was analyzed by mass spectrometry 
to quantify 78 HDL-bound proteins. This volcano plot displays 
the differences in protein abundance detected between the 
healthy controls (HC) and T1DM subjects. Each point represents 
one of the 78 detected proteins. Green points are proteins with 
positive fold change (i.e. increase in T1DM) and red points are 
negative fold changes. Horizontal dotted lines indicate statistical 
thresholds for a false discovery rate (FDR) of 5% by the method of 
Benjamini, Krieger and Yekutieli or a P-value < 0.05 calculated using 
two-tailed t-test without adjustment for multiple comparisons. 
A1BG alpha-1B-glycoprotein, APOA4 apolipoprotein A-IV, FHR2 
factor-H related protein 2, ITIH4 inter-alpha trypsin inhibitor 4, 
PGRP2 peptidoglycan recognition protein 2, ALBU albumin, CO3 
complement C3, CFAH complement factor H
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subjects. Comparison of proteins levels among the three 
subgroups revealed four different trends: (1) the pro-
tein is elevated in patients with T1DM and not affected 
by glycemic control (FHR2; Fig.  2a). (2) The protein is 
elevated in T1DM and partially returns to normal with 
glycemic control (A1BG; Fig.  2b). (3) The protein only 
differs in patients with well-controlled T1DM, suggest-
ing possible effect of exogenous insulin (CO3 and ALBU; 
Fig.  2c, d). (4) The proteins are not affected by T1DM 
control status (ITIH4, PGRP2, APOA4, CFAH; Fig.  2e–
h). A bimodal distribution of ITIH4 was apparent in sub-
jects with poorly controlled T1DM (Fig.  2e). To further 
examine this effect, we isolated these two subpopulations 
and reanalyzed the relationship among the three groups. 
ITIH4 in subjects with poorly controlled T1DM and 
low ITIH4 was not different compared to HC (Fig.  3a). 
However, the poorly controlled T1DM subjects with 
high ITIH4 had significantly greater ITIH4 than HC and 
well-controlled T1DM subjects (Fig.  3b). Linear regres-
sion analysis of the cohort with the poorly controlled low 
ITIH4 subjects removed revealed a striking correlation 
between HDL-bound ITIH4 and HbA1c (Fig. 3c). Patient 
data including sex, BMI, hsCRP, or duration of diabetes 
did not correlate with ITIH4 high/low status.
Overall, five proteins were determined to be influenced 
by T1DM and glycemic control: CO3, ITIH4, A1BG, FHR2, 
and ALBU. These proteins were annotated with known 
functions using PANTHER protein classifications (version 
14.0) (Fig.  4) [22]. The most represented protein classes 
are protease inhibitor (3/5), serine protease inhibitor (2/5), 
and complement component (2/5). Function enrichment 
analysis was performed using the PANTHER overrepre-
sentation analysis with Fisher’s Exact test and FDR correc-
tion [23]. This analysis compares the frequency of protein 
class assignments within a list of proteins to the frequency 
of those function classes in the entire human proteome. 
The HDL-associated proteins altered by T1DM contains 
a significant enrichment of protease inhibitor (P = 0.0076, 
FDR adjusted) and serine protease inhibitor (P = 0.023, 
FDR adjusted).
Cholesterol efflux analysis
As an indicator of HDL function, cholesterol efflux capac-
ity (CEC) to apoB depleted plasma was measured. No dif-
ferences in CEC were detected between the HC and T1DM 
groups (Additional file 3: Figure S1). Additionally, proteins 
influenced by T1DM status did not correlate with CEC.
Discussion
This report describes, for the first time, proteomic altera-
tions of HDL in a cohort of young adults with T1DM. We 
have identified several HDL-bound proteins that are signif-
icantly affected in patients with T1DM. We observed three 
clear trends in those affected proteins. FHR2 was increased 
in T1DM and not corrected by glucose control. This may 
suggest that this is caused by some consequence of the 
underlying condition and not circulating glucose levels. 
A1BG and ITIH4 were increased in T1DM and partially 
corrected by glucose control. Finally, CO3 and ALB are 
decreased in T1DM patients with well-controlled glucose. 
This may suggest the administration of insulin is influenc-
ing the association of these proteins with HDL.
Gene ontology analysis using PANTHER protein classi-
fications revealed a significant enrichment of proteins with 
protease inhibitor function, particularly serine protease 
inhibitors. This indicates that the effect of T1DM on the 
HDL proteome may specifically influence the protease reg-
ulator activity of HDL. Protease regulator activity on HDL 
has been previously suggested to play an important role 
in atherosclerotic cardiovascular disease [24]. The follow-
ing paragraphs discuss some potential roles for each of the 
affected proteins in HDL function and CVD risk.
FHR2, is a complement factor H (CFAH) related pro-
tein that resembles structurally and immunologically the 
complement factor H. While the complement pathway 
is a critical component of innate immunity, inappropriate 
complement activation has been linked to inflammation, 
Table 2 Linear regression of  HbA1c with  HDL-bound 
proteins
P values adjusted for multiple comparisons by Bonferroni method
Protein Slope R square P value Adjusted P
A1BG 0.026 ± 0.008 0.23 0.0019 0.015
FHR2 0.076 ± 0.031 0.14 0.020 0.16
PGRP2 0.039 ± 0.021 0.09 0.064 0.51
ITIH4 0.024 ± 0.013 0.09 0.069 0.55
CFAH 0.031 ± 0.017 0.08 0.074 0.59
APOA4 0.013 ± 0.008 0.07 0.10 0.81
CO3 − 0.014 ± 0.011 0.04 0.20 1.60
ALBU − 0.008 ± 0.009 0.02 0.41 3.26
Fig. 2 Effects of glycemic control on HDL-bound proteins. T1DM participants were separated into those with either “poor” or “optimal” glycemic 
control and levels of HDL-bound proteins detected by mass spectrometry were compared with healthy controls (HC) by one-way ANOVA with 
Dunnett’s correction for multiple comparisons. a FHR2 factor-H related protein 2; b A1BG alpha-1B-glycoprotein; c CO3 complement C3; d ALBU 
albumin; e ITIH4 inter-alpha trypsin inhibitor 4; f PGRP2 peptidoglycan recognition protein 2; g APOA4 apolipoprotein A-IV; h CFAH complement 
factor H  *P < 0.05; **P < 0.01; n.s. indicates not statistically significant
(See figure on next page.)
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diabetes, insulin resistance, atherosclerosis, and cardio-
metabolic diseases [25, 26]. Complement factor H is an 
important regulatory protein and prevents tissue damage 
from inappropriate complement activation [27]. Recently, 
it was shown that factor H binds to ApoE on HDL and 
this plays a role in regulating complement activation [28]. 
Furthermore, CFAH presence has also been linked with 
decreased insulin production from rat pancreatic cells 
and it may play a role in the pathogenesis of diabetes [27]. 
Whether the increased FHR2 in HDL of T1DM patients 
is related to the pathogenesis of T1DM remains to be 
explored. FHR2 has been previously detected on lipopro-
teins and it is thought to facilitate the adhesive response 
of neutrophils to lipopolysaccharides [27]. It is also pos-
sible that complement factor H and complement factor H 
related proteins (such as FHR2) play a role in lipid trans-
port and regulate lipid homeostasis [29]. The mechanism 
by which CFAH and FHR2 interact to regulate HDL func-
tion in diabetes requires further investigation.
A1BG, alpha-1-B glycoprotein, belongs to the immuno-
globulin family and its function is largely unknown [30, 
31]. A1BG was found to be overexpressed in tissues of 
pancreatic ductal adenocarcinoma and liver cancer cell 
lines [30], while it was not detected in normal pancre-
atic tissue and hence could be useful as a tumor marker. 
A1BG was also reported to be elevated in the urine of 
normoalbuminuric patients with T1DM when compared 
to healthy controls; however, the urine levels of this 
protein did not correlate with HbA1c or urine microal-
bumin [31]. Whether this protein could serve as a urine 
biomarker of early diabetic kidney disease remains to be 
examined. Interestingly, pharmacogenomic studies have 
shown that polymorphisms in the A1BG gene can play a 
role in cardiovascular outcomes of patients treated with 
antihypertensive medications [32].
ITIH4, inter-alpha-trypsin inhibitor heavy chain H4, 
belongs to the liver-restricted serine protease inhibitor 
family. It is highly expressed in liver development and 
Fig. 3 ITIH4 displays a unique bimodal distribution in T1DM subjects with poor glycemic control. a, b T1DM subjects with poor glycemic control 
were separated into ITIH4-Low and ITIH4-High groups and compared separately with the other groups by one-way ANOVA with Dunnett’s 
correction for multiple comparisons. c Linear regression analysis of entire cohort with T1DM poor (ITIH4-Low) subjects removed. *P < 0.05; **P < 0.01; 
***P < 0.001; n.s. indicates not statistically significant. ITIH4 inter-alpha trypsin inhibitor 4
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Fig. 4 Functional classifications of HDL-associated proteins affected 
by T1DM. PANTHER protein classification system was used to identify 
known functions of each of the proteins altered by T1DM in this 
study. CO3 complement C3, ITIH4 inter-alpha trypsin inhibitor 4, A1BG 
alpha-1B-glycoprotein, FHR2 factor-H related protein 2, ALBU albumin
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low levels have been found in hepatocellular and ovarian 
cancer [33, 34]. ITIH4 is elevated in urine of patients with 
T2DM and microalbuminuria and could possibly serve as 
a biomarker for diabetic kidney disease [35]. ITIH4 was 
also found to be downregulated after a very low caloric 
diet in patients with T2DM, possibly representing a bio-
marker of metabolic improvement [36].
We were unable to identify a clinical basis for the 
bimodal distribution of ITIH4 in the poorly controlled 
T1DM cohort. Using logistic regression analysis, high 
vs low ITIH4 grouping does not appear to correlate with 
age, sex, BMI, hsCRP, or duration of diabetes. However, 
the high ITIH4 group, which made up 66% of the poorly 
controlled cohort displayed a robust elevation compared 
to HC that, similar to A1BG, was partially corrected with 
glycemic control. These results suggest that better gly-
cemic control could reverse the changes associated with 
overexpression of A1BG and ITIH4 on HDL. The fact 
that some protein alterations can be corrected by glyce-
mic control and others cannot indicates that these HDL 
proteome effects may be mediated by different mechanis-
tic pathways. Future studies could examine how glycemic 
control alters HDL structure and function and explore 
novel mechanisms to improve CVD risk in T1DM.
ALBU, albumin, is the most abundant protein in the 
plasma and binds to electrolytes, hormones, fatty acids 
and drugs. Relatively low serum albumin has also been 
used as a marker of increased mortality from CVD [37, 
38]. Serum albumin has been found to be positively cor-
related with HDL and total cholesterol, and it is possible 
that low serum albumin reflects abnormalities in lipid 
metabolism and function [39]. Interestingly, glycated 
albumin was shown to decrease the anti-inflammatory 
function of HDL and impair the reversed cholesterol 
transport function, contributing to the development of 
CVD in patients with diabetes [40]. Whether the low 
albumin on HDL we found in our patients with T1DM 
reflects an imbalance between glycosylated and non-gly-
cosylated forms of albumin requires further study.
CO3, complement factor 3, is produced by mac-
rophages and plays a key initiating role in the activa-
tion of complement on the vascular endothelium, 
which triggers an inflammatory response, creating a 
vessel wall that is prone to atherosclerosis and increas-
ing CVD risk [26]. CO3 has been previously detected 
on HDL [10, 41]. Vaisar et al. reported multiple com-
plement regulatory proteins on HDL fractions [41]. 
Interestingly, in their study, subjects with cardiovascu-
lar disease had significantly elevated levels of CO3 on 
HDL fractions [41]. Others have shown that increased 
CO3 on HDL of patients with CVD, psoriasis and 
rheumatoid arthritis is linked to decreased cholesterol 
efflux [10, 42, 43]. Additionally, HDL-bound CO3 has 
been correlated with increased non-calcified plaque 
burden in patients undergoing coronary CT angiogra-
phy [44]. The current study found lower CO3 in T1DM 
compared to HC (although statistically significant only 
in the “well-controlled” glycemic cohort), which sug-
gests a protective effect of insulin given the evidence 
in literature. This could represent a protective role of 
HDL against CVD in T1DM subjects during the early 
stages of disease.
Both ALBU and CO3 were significantly lower only 
in the group of T1DM with optimal control compared 
to HC, suggesting that perhaps higher doses of insu-
lin may play a role in altering their values. Insulin can 
increase the transcapillary escape of albumin as well as 
the urinary excretion of albumin and whether the lower 
albumin and CO3 on HDL could be secondary to these 
mechanisms requires further investigation [45, 46].
Strengths of our study include that this is a well-char-
acterized cohort of youth with T1DM, with optimal 
and suboptimal glycemic control, along with detailed 
HDL proteome data. The combination of two-step size-
exclusion chromatography and lipid interaction based 
HDL purification and SWATH-MS provides sensitive 
and robust label-free proteomic quantitation for mul-
tiple clinical samples. Limitations include the small 
sample size and lack of full functional studies for each 
protein of interest. Our goal for this project was to pro-
vide an initial characterization of the proteomic differ-
ences in HDL composition between youth with T1DM 
and HC and identify associations with glycemic con-
trol. Future studies will further investigate the func-
tional roles of the identified proteins that differed on 
HDL from T1DM patients.
Our group has previously published differences in the 
cholesterol efflux values between T1DM and HC in a 
larger cohort [8], but in this particular subset of par-
ticipants we did not detect differences in cholesterol 
efflux, potentially because of the smaller sample size, 
the well-controlled status in half of the T1DM partici-
pants and their short diabetes duration. There were no 
significant correlations between the specific proteins of 
interest and cholesterol efflux. The lack of a group wide 
effect on HDL’s cholesterol efflux capacity, is not neces-
sarily surprising considering that the HDL-cholesterol 
levels are not different in this cohort and the protein 
changes detected here do not include proteins known 
to influence efflux (e.g. apoA-I, serum amyloid A, etc.) 
[44, 47]. Based on our functional classification analysis, 
it seems likely the influence of T1DM on HDL may be 
more strongly tied to HDL’s roles in protease regulation 
and inflammation [24].
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Conclusions
In summary, we found altered protein composition of 
HDL in youth with T1DM compared to HC by combin-
ing size-exclusion chromatography-based HDL puri-
fication and SWATH-MS-based label-free proteomic 
quantitation. The specific proteomic changes suggest a 
possible connection with increased risk for cardiovas-
cular disease, via multiple pathways relevant to known 
functions associated with the affected proteins. Future 
studies should examine the specific role of each protein 
on altering known functions of HDL such as anti-inflam-
matory activity, cholesterol efflux capacity, and pre-
vention of oxidation of LDL or the exploration of novel 
HDL functions. Larger epidemiologic studies could also 
examine the association of the altered HDL proteins with 
cardiovascular events. Finally, the association of glyce-
mic control with some of these HDL associated proteins 
suggests the possibility that better glycemic control could 
reverse compositional abnormalities of HDL and poten-
tially decrease CVD risk by restoring HDL function.
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